Rifampicin-resistant Mycobacterium tuberculosis: susceptibility to isoniazid and other anti-tuberculosis drugs [Short communication]
| Autor: | Lucía Barrera, Richard Lumb, N S Shah, A Santos Silva, Nuria Martín-Casabona, Francis Drobniewski, Ekaterina V. Kurbatova, F Arias, Elvira Richter, A. Van Deun, Fadila Boulahbal, J P Cegielski, Beverly Metchock, I Zemanova, Chris Coulter, Abigail Wright, Hyun-Chul Kim, Joseph S. Cavanaugh |
|---|---|
| Rok vydání: | 2012 |
| Předmět: |
Pulmonary and Respiratory Medicine
Tuberculosis Rifabutin biology business.industry Isoniazid Rifampicin resistance Drug resistance bacterial infections and mycoses medicine.disease biology.organism_classification Virology Microbiology Mycobacterium tuberculosis Infectious Diseases Tuberculosis diagnosis polycyclic compounds medicine business Rifampicin medicine.drug |
| Zdroj: | The International Journal of Tuberculosis and Lung Disease. 16:355-357 |
| ISSN: | 1815-7920 1027-3719 |
| Popis: | Based on data from 14 Supranational Tuberculosis (TB) Reference Laboratories worldwide, the proportion of rifampicin-resistant isolates that were isoniazid-susceptible by phenotypic drug-susceptibility tests varied widely (0.5%–11.6%). Rifampicin-resistant isolates that were isoniazid-susceptible had significantly lower rates of resistance to other first-line and second-line anti-TB drugs (except rifabutin) compared to multidrug-resistant isolates. Rifampicin resistance is not always a good proxy for a presumptive diagnosis of multidrug-resistant tuberculosis, which has implications for use of molecular assays that identify only rifampicin resistance-associated DNA mutations. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|